The firm recently concluded a “pay for delay” class action against pharmaceutical companies that manufacture Aggrenox, a stroke medication. The complaint alleges that the manufacturer paid generic manufacturers to delay the introduction of a generic form of the medication, resulting in harm to stroke patients. Class counsel, including Keith Dubanevich, obtained a $54 million settlement on behalf of the class.
Menu